1. Home
  2. TCPC vs CADL Comparison

TCPC vs CADL Comparison

Compare TCPC & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock TCP Capital Corp.

TCPC

BlackRock TCP Capital Corp.

HOLD

Current Price

$4.37

Market Cap

407.2M

Sector

Finance

ML Signal

HOLD

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$7.18

Market Cap

357.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCPC
CADL
Founded
2006
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
407.2M
357.4M
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
TCPC
CADL
Price
$4.37
$7.18
Analyst Decision
Sell
Strong Buy
Analyst Count
2
7
Target Price
$3.50
$19.00
AVG Volume (30 Days)
1.2M
1.2M
Earning Date
05-07-2026
05-12-2026
Dividend Yield
17.55%
N/A
EPS Growth
N/A
58.62
EPS
N/A
N/A
Revenue
N/A
$125,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.43
$4.34
52 Week High
$8.05
$7.24

Technical Indicators

Market Signals
Indicator
TCPC
CADL
Relative Strength Index (RSI) 66.86 81.28
Support Level $3.43 $5.25
Resistance Level $5.99 $7.24
Average True Range (ATR) 0.16 0.35
MACD 0.11 0.22
Stochastic Oscillator 89.62 85.02

Price Performance

Historical Comparison
TCPC
CADL

About TCPC BlackRock TCP Capital Corp.

BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Share on Social Networks: